Norgen Biotek Breaking News BioArctic Doses First Parkinson's Patient in Trial of Alpha-Synuclein-Targeting Drug Avistone Biotechnology to Begin Trial of Next-Generation ROS1/NTRK Inhibitor Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests In Brief This Week: Mount Sinai, AAVantgarde Bio, Lantern Pharma, Exegenesis Bio, AlveoGene Foresight Diagnostics Launches Lymphoma Personalized Treatment Clinical Trial
